How pharmaceutical companies profit from drugs for rare diseases
By: Dyfrig Hughes (Professor of Pharmacoeconomics, Co-director of the Centre for Health Economics & Medicines Evaluation, Bangor University) & Jannine Poletti-Hughes (Lecturer in Accounting and Finance, University of Liverpool) Pharmaceutical companies’ traditional focus on discovering the next US$1 billion “blockbuster” drug has shifted in recent years, from products for common diseases to treatments for rare…
